INNOCARE (688428.SH): Releases Phase II Clinical Data of Novel BTK Inhibitor Obutinib on Forum.

26/02/2025

Nuocheng Jianhua (688428.SH) announced that the company will attend the 10th Americas Multiple Sclerosis Annual Meeting in 2025...

INNOCARE (688428.SH) announced that at the 10th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum in 2025, they will present Phase II clinical data for a new BTK inhibitor, orelabrutinib, for the treatment of relapsing-remitting multiple sclerosis (RRMS). The data will be presented in a live poster session on February 27th, Eastern Time (poster code: P094). The research results demonstrate that orelabrutinib has shown high efficacy in treating RRMS patients. The daily dose of 80mg orelabrutinib once a day has shown the best therapeutic effects and safety, and will therefore be used as the dosage for the Phase III clinical trial of orelabrutinib in treating progressive multiple sclerosis (PMS).

Huachu Securities: Shunfeng (06936) continues to lead in the volume growth rate in June, pay attention to investment opportunities in the express delivery sector under the "anti-inner loop" trend.

Guosen: How to make absolute return investments in a low interest rate environment?

Preview of new stocks in the US stock market | Industry anti-involvement helps to repair the fundamentals, how does New Subee Optoelectronics (XZ.US) break into the top tier of the industry?

Huachu Securities: Shunfeng (06936) continues to lead in the volume growth rate in June, pay attention to investment opportunities in the express delivery sector under the "anti-inner loop" trend.

Guosen: How to make absolute return investments in a low interest rate environment?

Preview of new stocks in the US stock market | Industry anti-involvement helps to repair the fundamentals, how does New Subee Optoelectronics (XZ.US) break into the top tier of the industry?